Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for renal cell carcinoma.

A Belldegrun1, R Figlin, J Danella

  • 1Department of Surgery, University of California, Los Angeles School of Medicine.

Seminars in Urology
|February 1, 1992
PubMed
Summary

Immunotherapy shows promise for metastatic renal cell carcinoma, offering a new treatment avenue. Advances in immunology and molecular biology support its potential effectiveness for patients with this cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

T-cell recruitment: a tool for specific immunosuppression.

Immunology today·2014
Same author

Immunotherapy and gene therapy for genitourinary malignancies.

International journal of urology : official journal of the Japanese Urological Association·2013
Same author

Interferon Alpha, GM-CSF-Activated T Cells, and IL-6 in Renal Cell Carcinoma.

Methods in molecular medicine·2011
Same author

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.

British journal of cancer·2006
Same author

Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas.

Reviews in urology·2006

Area of Science:

  • Oncology
  • Immunology

Background:

  • Metastatic renal cell carcinoma (mRCC) historically has a poor prognosis.
  • Immunotherapy is emerging as a potential treatment modality for mRCC.

Purpose of the Study:

  • To review the current and emerging role of immunotherapy in managing metastatic renal cell carcinoma.
  • To highlight promising therapeutic strategies including cytokine therapy, adoptive immunotherapy, and gene therapy.

Main Methods:

  • Review of current literature on immunotherapy for mRCC.
  • Analysis of investigational therapeutic approaches.

Main Results:

  • Immunotherapy presents a viable alternative treatment for mRCC.
  • Cytokine monotherapy, combination therapy, adoptive immunotherapy, and gene therapy show promise.

Conclusions:

  • The prognosis for mRCC patients may improve with immunotherapy.
  • Ongoing advancements in immunology and molecular biology are expected to enhance immunotherapy efficacy.

Related Experiment Videos